Metraipolis › archive › dc_87192cb8383d
Ashley Van Zeeland — Wikipedia (en)
- Source
- Wikipedia (en)
- Original
- https://en.wikipedia.org/wiki/Ashley_Van_Zeeland
- License (as archived)
- CC-BY-SA-4.0
- Archived
- 2026-11-10T03:24:22.762Z
- SHA-256 of the archived text
228bd2c2ee33631eb1ee7fb9f3ce47f3b0ccfb35dd8446ab38a511421c6b3a38- Stable URL of this page
https://metraipolis.com/documento/dc_87192cb8383d
How to cite
Ashley Van Zeeland — Wikipedia (en) — Wikipedia (en), https://en.wikipedia.org/wiki/Ashley_Van_Zeeland (CC-BY-SA-4.0); archived copy: https://metraipolis.com/documento/dc_87192cb8383d (Metraipolis archive dc_87192cb8383d, sha256 228bd2c2ee33631eb1ee7fb9f3ce47f3b0ccfb35dd8446ab38a511421c6b3a38)
BibTeX
@misc{dc87192cb8383d,
title = {Ashley Van Zeeland — Wikipedia (en)},
howpublished = {Wikipedia (en)},
url = {https://en.wikipedia.org/wiki/Ashley_Van_Zeeland},
note = {License CC-BY-SA-4.0; archived copy https://metraipolis.com/documento/dc_87192cb8383d; sha256 228bd2c2ee33631eb1ee7fb9f3ce47f3b0ccfb35dd8446ab38a511421c6b3a38},
year = {2026}
}Archived text
Reproduced under CC-BY-SA-4.0. Attribution: Wikipedia (en), https://en.wikipedia.org/wiki/Ashley_Van_Zeeland. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
Ashley Van Zeeland is an American biotechnology executive. As of 2026, she is a vice president for American biotechnology company Illumina and the head of global strategic accounts. She previously worked as a neuroscientist, with her research focusing on genomics, genetics, and biotechnology in the fields of autism and anorexia nervosa. Her work on autism revealed that genetic variants were linked to different communication pathways within the brain, and her work related anorexia nervosa to an enzyme regulating cholesterol metabolism. She co-founded Cypher Genomics in March 2011 with Eric Topol, Nicholas Schork, and Ali Torkamani in La Jolla, California. She was the CEO of Cypher Genomics, which partnered with the Clinic for Special Children in Strasburg, Pennsylvania to diagnose rare genetic diseases among Amish and Mennonite patients, a population with a relatively high incidence of genetic disease. She left the company in October 2017 after its acquisition by Human Longevity. Zeeland joined Illumina in 2018 initially as a vice president for "Product Development Business Operations & Systems Integration". In 2022, she became the VP for the Illumina Open Innovation division and the VP of corporate development in 2023. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (deposito sistematico; retro-catalogo: tutte le voci di Wikipedia in inglese, in ordine alfabetico). Fonte: Wikipedia in inglese, voce «Ashley Van Zeeland» — https://en.wikipedia.org/wiki/Ashley_Van_Zeeland Wikidata Q4805617: «neuroscientist» (dati Wikidata in CC0 1.0) — https://www.wikidata.org/wiki/Q4805617 Autori: i contributori di Wikipedia (cronologia: https://en.wikipedia.org/wiki/Ashley_Van_Zeeland?action=history). Licenza: Creative Commons Attribuzione-Condividi allo stesso modo 4.0 (CC BY-SA 4.0) — https://creativecommons.org/licenses/by-sa/4.0/. Il riuso richiede attribuzione e stessa licenza. Estratto dell'introduzione non modificato nel contenuto; revisione 1377333464, consultata il 2026-11-10T03:21:27.411Z tramite l'API ufficiale di Wikipedia. Impronta SHA-256 dell'estratto: ba3a8d929c1591d3ad1bcc80ffa2df7290c2cd64741f4a360bf8ecb1393f486c